Premium
Amiloride in primary hyperaldosteronism
Author(s) -
Gritting George T,
Cole Alan G,
Aurecchia Steven A,
Sindler Bruce H,
Komanicky Pavel,
Melby James C
Publication year - 1982
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1982.9
Subject(s) - hyperaldosteronism , amiloride , primary (astronomy) , medicine , aldosterone , chemistry , sodium , organic chemistry , physics , astronomy
Amiloride is a potassium‐sparing diuretic used in spontaneous and diuretic‐induced hypokalemia. The effect of amiloride was studied prospectively in 12 patients with primary hyperaldosteronism. Four patients had unilateral adrenal adenomas and eight had bilateral adrenal hyperplasia. All patients were hypertensive and their mean plasma potassium levels were low. Amiloride, 10 to 40 mg daily, was given for 6 mo. Mean plasma potassium levels rose (0.96 mEq/l, P < 0.001) and remained normal throughout the study without potassium supplementation. Mean blood pressure was lowered by amiloride (22/10 mm Hg, P < 0.001) but normotension required concomitant antihypertensive therapy in most patients. No significant adverse clinical or laboratory experiences could be directly attributed to amiloride therapy. There was no correlation between the response to therapy and the plasma aldosterone levels, aldosterone secretion rate, or presence of a unilateral adrenal adenoma. Our study demonstrates the efficacy of amiloride in the correction of hypokalemia and amelioration of hypertension in primary hyperaldosteronism. Clinical Pharmacology and Therapeutics (1982) 31 , 56–61; doi: 10.1038/clpt.1982.9